The Longevity Drug 150 Million People Are Already Taking

Novo Nordisk sold $8 billion worth of Wegovy in 2024. That's not an obesity number. That's a longevity number.

I want to be precise about this, because the category confusion matters. When a drug prescribed for weight loss turns out to independently reduce cardiovascular death by 20%, kidney disease progression by 24%, and sleep apnea severity by roughly 60%, we are no longer talking about a diet pill. We are talking about what may be the most broadly effective intervention against aging-related disease since statins. And unlike the $40 billion flowing into longevity startups chasing reprogramming factors and senolytics in mice, GLP-1 agonists are already inside 150 million human bodies generating real-world outcomes data at a scale no clinical trial can match.

The Trial Scorecard

I've spent the last six months compiling every major GLP-1 outcome trial. The pattern is striking not for what succeeded, but for how many organ systems responded to a single mechanism.

Trial	Drug	Target	Result	N
SELECT (2023)	Semaglutide 2.4mg	MACE (heart attack, stroke, CV death)	−20% vs placebo	17,604
FLOW (2024)	Semaglutide 1.0mg	Kidney disease progression (CKD + T2D)	−24% vs placebo	3,533
SURMOUNT-OSA (2024)	Tirzepatide	Sleep apnea events (AHI)	−~60%	469
ESSENCE (ongoing)	Semaglutide	MASH (fatty liver disease)	Resolution in ~60% at 72wk (interim)	~1,200
EVOKE (2025)	Semaglutide	Alzheimer's progression	Failed. No significant slowing.	1,840

Read that table carefully. Four organ systems improved. One didn't. The Alzheimer's failure matters — I'll get to it — but the honest read of this data is that a single drug class is producing clinically meaningful effects across cardiovascular, renal, hepatic, and respiratory disease in trials enrolling thousands. That is extremely unusual.

The Part Nobody Saw Coming

SELECT is the trial that changed the conversation. 17,604 overweight or obese adults without diabetes, randomized to semaglutide or placebo, followed for a mean of 39.8 months. Primary endpoint: a 20% reduction in MACE — major adverse cardiovascular events. Heart attacks. Strokes. Cardiovascular death.

Twenty percent. In people who weren't diabetic. With a drug originally developed for blood sugar.

What made cardiologists sit up was the subgroup analysis from the National Lipid Association meeting in 2025: the cardiovascular benefits appear to operate independently of weight loss itself. Patients who lost minimal weight still showed risk reduction. Something else is happening at the receptor level — reduced arterial inflammation, improved endothelial function, direct effects on atherosclerotic plaque. The weight loss might be a side effect of the actual mechanism, not the other way around.

The $8 Billion Misunderstanding

Novo Nordisk reported $41 billion in total revenue for 2024. Wegovy alone — the obesity-branded semaglutide — accounted for 58.2 billion DKK, roughly $8 billion, doubling year-over-year. Ozempic, the diabetes formulation of the same molecule, added tens of billions more. Eli Lilly's competing GLP-1, tirzepatide (Mounjaro/Zepbound), is on a similar trajectory.

Wall Street models this as an obesity market. Goldman Sachs projects GLP-1s reaching $100 billion in annual sales by 2030. But the addressable population keeps expanding because the clinical indications keep expanding. The FDA has already approved semaglutide for cardiovascular risk reduction (based on SELECT), and CKD and MASH filings are expected in the next 12–18 months. Each approval widens the patient funnel and, critically, insurance coverage.

An obesity drug that costs $1,300/month out of pocket and struggles for insurance approval is a luxury product. A cardiovascular drug with a 20% MACE reduction and an NNT of ~50 is a medical necessity that payers will cover. Same molecule. Different economics.

Where It Failed, and Why That Matters

EVOKE. 1,840 patients with early-stage Alzheimer's, randomized to oral semaglutide (Rybelsus) or placebo. Novo Nordisk announced the results in November 2025: no statistically significant slowing of cognitive decline on the primary endpoint.

This was not a surprise to anyone reading the mechanistic literature carefully, though it was a surprise to the market. The observational data suggesting GLP-1 users had lower dementia rates was always confounded — people who maintain healthy metabolic profiles through any means tend to have better cognitive outcomes. EVOKE tested whether the drug could treat existing neurodegeneration, not prevent it. Different question entirely.

Novo noted that some biomarkers improved — tau levels, inflammatory markers, neuronal damage indicators. These are the kinds of partial signals that justify continued research but don't justify prescribing. The prevention hypothesis (treating metabolic risk factors decades before cognitive decline) remains plausible and untested. The treatment hypothesis is, for now, dead.

I bring this up because honest reporting requires it. A longevity drug that actually worked for everything would be too good to be true. The Alzheimer's failure makes the cardiovascular and renal successes more credible, not less.

The Pipeline Behind the Pipeline

Semaglutide is the beginning, not the ceiling. The next generation of GLP-1 agonists is already in trials:

CagriSema (Novo Nordisk) — combines semaglutide with a long-acting amylin analog. Early data shows 22.7% weight loss at 68 weeks versus 15.8% for semaglutide alone. Phase 3 results expected 2026.

Survodutide (Boehringer Ingelheim/Zealand) — dual GLP-1/glucagon agonist. 18.7% weight loss and promising MASH data. The glucagon component may accelerate hepatic fat clearance in ways semaglutide alone doesn't.

Orforglipron (Eli Lilly) — an oral small-molecule GLP-1 agonist. Not a peptide. This matters enormously: if it works, GLP-1 becomes a pill costing a fraction of the injectable, removing the access bottleneck that currently limits adoption to wealthy countries and insured patients.

The Longevity Reframe

I study aging for a living, and the longevity field has a credibility problem. Too many companies raising nine-figure rounds on mouse data and theoretical mechanisms. Altos Labs has $3 billion and no clinical trial. Calico has been funded for thirteen years with essentially no public pipeline. The TAME metformin trial is still enrolling.

Meanwhile, 150 million people are injecting a GLP-1 agonist every week, and the outcome data shows reductions in the leading causes of age-related death: cardiovascular disease, kidney failure, metabolic liver disease. Not in mice. In humans. In randomized controlled trials with five-digit enrollment.

The longevity community is looking for the molecule that will extend healthspan by intervening in the fundamental biology of aging. GLP-1 agonists may not be that molecule. But they are producing the largest measurable reduction in age-related mortality risk of any drug class introduced this century, and they're doing it right now, at scale, in the real world. That counts for something.

Sources & References

1. SELECT Trial: Semaglutide and Cardiovascular Outcomes — American College of Cardiology. N=17,604, 20% MACE reduction. Published in NEJM, November 2023. DOI: 10.1056/NEJMoa2307563
2. FLOW Trial: Semaglutide and Kidney Outcomes — ACC. N=3,533, 24% reduction in kidney disease progression (HR 0.76, 95% CI 0.66–0.88, p=0.0003). Published in NEJM, 2024.
3. Semaglutide Reduced Risk of Major Kidney Disease Events by 24% — American Diabetes Association press release on FLOW results.
4. SURMOUNT-OSA: Tirzepatide for Obstructive Sleep Apnea — ACC. N=469, approximately 50–60% AHI reduction. Published in NEJM, 2024.
5. ESSENCE Trial: Semaglutide for MASH — UIC Drug Information Group. Interim 72-week results: 62.9% MASH resolution vs 34.3% placebo. FDA accelerated approval August 2025.
6. EVOKE Trial: Semaglutide Fails to Outperform Placebo in Alzheimer's — NeurologyLive. N=1,840, announced November 24, 2025.
7. Novo Nordisk: EVOKE Phase 3 Trials Did Not Demonstrate Significant AD Reduction — Novo Nordisk press release, November 24, 2025.
8. Novo Nordisk 2024 Annual Report: $42.13 Billion Revenue — Echemi. Total 2024 revenue; Wegovy sales ~$8B (58.2B DKK).
9. Wegovy Sales Double as Restrictions Lift — Pharmaphorum. Wegovy 2024 revenue trajectory confirmation.
10. Analysts Weigh Obesity Drug Market Pegged at $100B by 2030 — GEN. Goldman Sachs projection for GLP-1 market.
11. CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE-1 Trial — HCP Live. Semaglutide + cagrilintide combination, 22.7% vs 16.1% semaglutide alone.
12. Survodutide Induces Up to 18.7% Weight Loss in Phase 2 Trial — Healio. Boehringer Ingelheim/Zealand dual GLP-1/glucagon agonist. Presented at EASD 2024.
13. What to Know About Orforglipron — Eli Lilly. Oral small-molecule GLP-1 agonist; Phase 3 results published in NEJM.
14. Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy — Eli Lilly investor release, June 2025. Complete Phase 3 ATTAIN results in NEJM.